EA Pharma Co., Ltd. clinical trials

Acquired by Eisai Co., Ltd.

The registry lists 13 studies whose lead sponsor is EA Pharma Co., Ltd.. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Apr 2, 2025.

Studies

Recruiting first, then most recently updated. Showing 13 of 13. All Eisai Co., Ltd. studies →

• A Study of E6011 in Participants With Active Crohn's DiseaseCompletedNCT03733314Phase 2

  Sponsor listed in the registry: EA Pharma Co., Ltd. · EA Pharma Co., Ltd. — acquired company within the Eisai Co., Ltd. group

• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Bioavailability, and Food-effects of EA1080 in Healthy Caucasian and Japanese Male ParticipantsCompletedNCT04223960Phase 1

  Sponsor listed in the registry: EA Pharma Co., Ltd. · EA Pharma Co., Ltd. — acquired company within the Eisai Co., Ltd. group

• A Study to Evaluate the Safety and Efficacy of AJM300 in Participants With Active Ulcerative ColitisCompletedNCT03531892Phase 3

  Sponsor listed in the registry: EA Pharma Co., Ltd. · EA Pharma Co., Ltd. — acquired company within the Eisai Co., Ltd. group

• A Phase 1/2 Study of Repeated Intravenous E6011 Administration in Japanese Subjects With Crohn's DiseaseCompletedNCT02039063Phase 1/2

  Sponsor listed in the registry: EA Pharma Co., Ltd. · EA Pharma Co., Ltd. — acquired company within the Eisai Co., Ltd. group

• A Single Intravenous Dose of E3112 in Japanese Healthy Adult Male ParticipantsCompletedNCT03922633Phase 1

  Sponsor listed in the registry: EA Pharma Co., Ltd. · EA Pharma Co., Ltd. — acquired company within the Eisai Co., Ltd. group

• Study of E6007 in Japanese Patients With Moderate Active Ulcerative ColitisCompletedNCT03018054Phase 2

  Sponsor listed in the registry: EA Pharma Co., Ltd. · EA Pharma Co., Ltd. — acquired company within the Eisai Co., Ltd. group

• Study of E6011 in Japanese Subjects With Primary Biliary Cholangitis Inadequately Responding to Ursodeoxycholic AcidTerminatedNCT03092765Phase 2

  Sponsor listed in the registry: EA Pharma Co., Ltd. · EA Pharma Co., Ltd. — acquired company within the Eisai Co., Ltd. group

• A Single Intravenous Dose Study of E3112 in Japanese Healthy Adult Male SubjectsCompletedNCT03014895Early Phase 1

  Sponsor listed in the registry: EA Pharma Co., Ltd. · EA Pharma Co., Ltd. — acquired company within the Eisai Co., Ltd. group

• A Single Dose Study of E6130 in Japanese Healthy Adult Male SubjectsCompletedNCT02902978Phase 1

  Sponsor listed in the registry: EA Pharma Co., Ltd. · EA Pharma Co., Ltd. — acquired company within the Eisai Co., Ltd. group

• Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AJM347 in Healthy Male Caucasian and Japanese Subjects in the Fasted and Fed StateCompletedNCT03133468Phase 1

  Sponsor listed in the registry: EA Pharma Co., Ltd. · EA Pharma Co., Ltd. — acquired company within the Eisai Co., Ltd. group

• A Study to Determine the Absorption, Metabolism, and Excretion of [14C]-E6007 After a Single Oral Administration in Healthy Male ParticipantsCompletedNCT03444818Phase 1

  Sponsor listed in the registry: EA Pharma Co., Ltd. · EA Pharma Co., Ltd. — acquired company within the Eisai Co., Ltd. group

• A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics in Healthy Adult Male ParticipantsWithdrawnNCT03390647Phase 1

  Sponsor listed in the registry: EA Pharma Co., Ltd. · EA Pharma Co., Ltd. — acquired company within the Eisai Co., Ltd. group

• General Clinical Study of AJG555 in Pediatric Patients With Chronic ConstipationCompletedNCT02961556Phase 3

  Sponsor listed in the registry: EA Pharma Co., Ltd. · EA Pharma Co., Ltd. — acquired company within the Eisai Co., Ltd. group